All In Biotech

Drug Trial Radar · NCT05468320

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

51

Actual

Start

Nov 21, 2022

Primary completion

Dec 26, 2024

Study completion Dec 26, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary endpoint of remission in male and female participants aged 18 to 80 years with immune-mediated thrombotic thrombocytopenic purpura (iTTP). The anticipated study duration per participant without a recurrence while on therapy is maximum 24 weeks (ie, approximately 1 day for screening + maximum 12 weeks of treatment for the presenting episode + 12 weeks of follow-up). Participants will have daily assessments during hospitalization and weekly visits for assessments during ongoing treatment with caplacizumab and IST. There will be 3 outpatient visits for assessments during the follow-up period. There will be two additional follow-up visits for participants who do not have ADAMTS13 activity levels of ≥50% at the time of caplacizumab discontinuation.

Conditions

  • Thrombotic Thrombocytopenic Purpura

Interventions

  • CaplacizumabDrug

    Lyophilized powder for solution for injection.

  • CorticosteroidsDrug

    Solution for injection or Tablet

  • anti-CD20 antibodyBiological

    Solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study PeriodTime frame: From first dose of study treatment (Day 1) up to end of follow-up (up to approximately 24 weeks)

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama- Site Number : 8400011

    Birmingham, Alabama

  • Johns Hopkins University- Site Number : 8400007

    Baltimore, Maryland

  • Duke University Medical Center Site Number : 8400022

    Durham, North Carolina

  • The Ohio State University Comprehensive Cancer Center - Site Number : 8400001

    Columbus, Ohio

  • Investigational Site Number : 0560003

    Yvoir, Belgium

  • Investigational Site Number : 1240001

    Toronto, Ontario, Canada

  • Investigational Site Number : 2030001

    Brno, Czechia

  • Investigational Site Number : 2030003

    Prague, Czechia

  • Investigational Site Number : 2500002

    Bois-Guillaume, France

  • Investigational Site Number : 2500005

    Lille, France

  • Investigational Site Number : 2500003

    Paris, France

  • Investigational Site Number : 2500001

    Paris, France

  • Investigational Site Number : 2760006

    Berlin, Germany

  • Investigational Site Number : 2760002

    Cologne, Germany

  • Investigational Site Number : 2760001

    Frankfurt am Main, Germany

  • Investigational Site Number : 2760004

    Hanover, Germany

  • Investigational Site Number : 3800006

    Genova, Italy

  • Investigational Site Number : 3800005

    Verona, Italy

  • Investigational Site Number : 3800004

    Vicenza, Italy

  • Investigational Site Number : 3800003

    Avellino, Campania, Italy

  • Investigational Site Number : 3800001

    Milan, Lombardy, Italy

  • Investigational Site Number : 3920003

    Kurashiki-shi, Okayama-ken, Japan

  • Investigational Site Number : 3920001

    Iruma-gun, Saitama, Japan

  • Investigational Site Number : 5280002

    Amersfoort, Netherlands

  • Investigational Site Number : 7240001

    Madrid / Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 8260002

    Liverpool, United Kingdom

  • Investigational Site Number : 8260001

    London, London, City of, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.